221 related articles for article (PubMed ID: 24236993)
21. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.
Armstrong SC; Cozza KL
Psychosomatics; 2003; 44(2):167-71. PubMed ID: 12618536
[TBL] [Abstract][Full Text] [Related]
22. Bioavailability of morphine after administration of a new bioadhesive buccal tablet.
Beyssac E; Touaref F; Meyer M; Jacob L; Sandouk P; Aiache JM
Biopharm Drug Dispos; 1998 Sep; 19(6):401-5. PubMed ID: 9737821
[TBL] [Abstract][Full Text] [Related]
23. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone.
Cone EJ; Caplan YH; Moser F; Robert T; Black D
J Anal Toxicol; 2008 May; 32(4):319-23. PubMed ID: 18430301
[TBL] [Abstract][Full Text] [Related]
24. Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration.
Hedges AR; Pypendop BH; Shilo Y; Stanley SD; Ilkiw JE
J Vet Pharmacol Ther; 2014 Apr; 37(2):145-50. PubMed ID: 24745064
[TBL] [Abstract][Full Text] [Related]
25. Effects of subcutaneous methadone, morphine, buprenorphine or saline on thermal and pressure thresholds in cats.
Steagall PV; Carnicelli P; Taylor PM; Luna SP; Dixon M; Ferreira TH
J Vet Pharmacol Ther; 2006 Dec; 29(6):531-7. PubMed ID: 17083457
[TBL] [Abstract][Full Text] [Related]
26. Oxymorphone: a review.
Prommer E
Support Care Cancer; 2006 Feb; 14(2):109-15. PubMed ID: 16317569
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
Doodnaught GM; Monteiro BP; Benito J; Edge D; Beaudry F; Pelligand L; Steagall P
PLoS One; 2017; 12(4):e0176443. PubMed ID: 28445495
[TBL] [Abstract][Full Text] [Related]
28. Antinociceptive effects of intravenous administration of hydromorphone hydrochloride alone or followed by buprenorphine hydrochloride or butorphanol tartrate to healthy conscious cats.
Simon BT; Steagall PV; Monteiro BP; Troncy E; Lizarraga I
Am J Vet Res; 2016 Mar; 77(3):245-51. PubMed ID: 26919594
[TBL] [Abstract][Full Text] [Related]
29. Morphine and hydromorphone for postoperative analgesia: focus on safety.
Golembiewski JA
J Perianesth Nurs; 2003 Apr; 18(2):120-2. PubMed ID: 12710006
[No Abstract] [Full Text] [Related]
30. Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs.
Guedes AG; Papich MG; Rude EP; Rider MA
J Vet Pharmacol Ther; 2008 Aug; 31(4):334-43. PubMed ID: 18638294
[TBL] [Abstract][Full Text] [Related]
31. Effect of orally administered tramadol alone or with an intravenously administered opioid on minimum alveolar concentration of sevoflurane in cats.
Ko JC; Abbo LA; Weil AB; Johnson BM; Inoue T; Payton ME
J Am Vet Med Assoc; 2008 Jun; 232(12):1834-40. PubMed ID: 18598152
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
Vashi V; Harris S; El-Tahtawy A; Wu D; Cipriano A
J Clin Pharmacol; 2005 May; 45(5):547-54. PubMed ID: 15831778
[TBL] [Abstract][Full Text] [Related]
33. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
34. I.v. infusion of opioids for cancer pain: clinical review and guidelines for use.
Portenoy RK; Moulin DE; Rogers A; Inturrisi CE; Foley KM
Cancer Treat Rep; 1986 May; 70(5):575-81. PubMed ID: 2423236
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration.
Wells SM; Glerum LE; Papich MG
Am J Vet Res; 2008 Dec; 69(12):1548-54. PubMed ID: 19045999
[TBL] [Abstract][Full Text] [Related]
36. Use of oral oxymorphone in the elderly.
Guay DR
Consult Pharm; 2007 May; 22(5):417-30. PubMed ID: 17658959
[TBL] [Abstract][Full Text] [Related]
37. Long term methadone for chronic pain: a pilot study of pharmacokinetic aspects.
Fredheim OM; Borchgrevink PC; Klepstad P; Kaasa S; Dale O
Eur J Pain; 2007 Aug; 11(6):599-604. PubMed ID: 17113329
[TBL] [Abstract][Full Text] [Related]
38. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.
Smith MT
Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):524-8. PubMed ID: 10874511
[TBL] [Abstract][Full Text] [Related]
39. Bioavailability of tramadol hydrochloride after administration via different routes in rats.
Zhang H; Zhao Y; Wang X; Zhang Q
Biopharm Drug Dispos; 2014 Dec; 35(9):525-31. PubMed ID: 25170803
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration.
Di Cesare F; Gioeni D; Ravasio G; Pellegrini A; Lucatello L; Bisutti V; Villa R; Cagnardi P
J Vet Pharmacol Ther; 2019 Jul; 42(4):392-400. PubMed ID: 31197847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
